From Name

From Email

To Name

To Email

Message

FDA Expands Approval of STELARA to Treat Pediatric Plaque Psoriasis

from Contemporary Pediatrics

FDA Expands Approval of STELARA to Treat Pediatric Plaque Psoriasis Contemporary Pediatrics The US Food and Drug Administration expanded the indication for STELARA® (ustekinumab) to treat moderate-to-severe plaque psoriasis in children aged 6 to 11 years.1 The drug targets interleukin (IL)-12 and IL-23, which is key to moderating the overactive inflammatory response. The drug is given as an injection under the skin 4 times a year, following 2 starter doses. READ MORE

more